Columbus Venture Partners

DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system aimed at the early detection of sepsis. The company focuses on rapidly identifying pathogens and providing antibiogram results within hours. Utilizing artificial intelligence, DeepUll's system not only detects the causative infectious agents but also assesses the patient's immunological and functional status, allowing for predictive insights into the potential onset and progression of sepsis. This capability enables healthcare professionals to deliver timely clinical responses, even before symptoms manifest, ultimately improving patient outcomes and reducing the unnecessary use of antimicrobials.

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, focused on developing innovative therapies to enhance the effectiveness of anti-cancer treatments. Established in 2015, the company has created a proprietary small molecule drug known as LUT014, which acts as a topical B-Raf inhibitor. This drug facilitates the use of epidermal growth factor receptor (EGFR) inhibitors while minimizing the common cutaneous side effects typically associated with such treatments. By addressing these side effects, Lutris Pharma aims to improve both the efficacy of anti-cancer therapies and the overall quality of life for patients undergoing treatment with EGFR inhibitors.

Tolerance Bio is a biopharmaceutical company dedicated to extending healthspan by restoring and preserving the function of the thymus, a critical organ for immune system regulation. The company's innovative approach involves creating artificial, bio-engineered thymus tissue using induced pluripotent stem cells (iPSCs), which can then be used to establish and maintain immune tolerance in patients, potentially treating a wide range of immune-mediated diseases.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Established in 2019, the company specializes in creating quantum computing software that leverages probabilistic and nondeterministic technologies to address complex challenges in various sectors, particularly finance. Multiverse Computing's software solutions are designed for portfolio optimization, risk analysis, and market simulation, enabling clients in industries such as banking, energy, manufacturing, and logistics to harness the power of quantum computing. By focusing on these tailored applications, the company aims to facilitate advancements in solving financial and macro-economic problems, positioning itself as a key player in the emerging quantum technology landscape.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Integra Therapeutics is a biotechnology company focused on advancing gene editing technologies to address various diseases. It develops innovative gene writing tools that enhance the capabilities of gene therapy, aiming to meet the specific needs of patients. By integrating the precision of CRISPR systems with the efficiency of viral integrases and transposases, Integra Therapeutics seeks to overcome existing limitations in gene editing. The company's approach enables scientists to introduce DNA into genomes using sequence-specific DNA binding proteins, facilitating the development of more effective gene therapies.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, founded in 2012. The company specializes in the development of neurokinin (NK) receptor antagonists, focusing on innovative treatments for conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at alleviating intense pruritus induced by targeted anti-cancer therapies. NeRRe's pipeline also includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, which is prepared for Phase I trials as an NK-1 antagonist, and NT-432, a clinical candidate. By developing first-in-class therapies, NeRRe Therapeutics seeks to address chronic and debilitating conditions, providing medical professionals with effective solutions for patients suffering from refractory or unexplained cough and other related ailments.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Highlight Therapeutics is a private, clinical-stage company focused on developing RNA-based immuno-oncology therapies aimed at treating cancer. The company’s innovative therapies mimic the effects of viral infections to enhance the efficacy of existing cancer treatments, thereby facilitating faster tumor recovery in patients. By leveraging the potential of immuno-oncology, Highlight Therapeutics seeks to improve patient outcomes and contribute to advancements in cancer care.

Artax Biopharma Inc. is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. Incorporated in 2013 and headquartered in Cambridge, Massachusetts, the company specializes in small-molecule drugs that modulate immune responses. Its lead compound, AX-024, selectively inhibits the interaction between T-cell receptors and Nck, which plays a crucial role in T-cell activation. This mechanism allows for the suppression of harmful immune reactions against self-tissues while maintaining the body's ability to combat infections. Artax Biopharma’s research portfolio includes therapies targeting conditions such as asthma, rheumatoid arthritis, psoriasis, graft-versus-host disease, and multiple sclerosis, aiming to provide innovative treatments with reduced side effects for patients suffering from these complex health issues.

Sanifit Therapeutics S.A. is a clinical-stage biopharmaceutical company dedicated to developing treatments for progressive vascular calcification disorders. Its primary product, SNF472, is a novel small molecule aimed at treating calciphylaxis, a serious condition affecting patients undergoing dialysis. In addition to SNF472, the company's pipeline includes Lit-Control, a medical device designed to enhance the quality of life for patients with renal lithiasis through self-monitoring of urinary pH; ASB-01, an oral and dental health solution; SNF671, a food supplement for promoting bone health; and Phytech, an implant surface treatment that incorporates bioactive molecules. Founded in 2004 and headquartered in Palma de Mallorca, Spain, Sanifit also operates an office in San Diego, California, and has expanded its activities into Switzerland since its inception.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.